These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24247419)

  • 1. A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer.
    Mizushima T; Ide Y; Murata K; Ohashi I; Yasumasa K; Fukunaga M; Takemoto H; Tamagawa H; Hasegawa J; Hata T; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Oncology; 2013; 85(6):317-22. PubMed ID: 24247419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
    Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
    Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
    Komatsu Y; Yuki S; Sogabe S; Fukushima H; Nakatsumi H; Kobayashi Y; Iwanaga I; Nakamura M; Hatanaka K; Miyagishima T; Kudo M; Munakata M; Meguro T; Tateyama M; Sakata Y
    Acta Oncol; 2012 Sep; 51(7):867-72. PubMed ID: 22554343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
    Yamada Y; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Kato K; Hamaguchi T; Shimada Y
    Invest New Drugs; 2012 Aug; 30(4):1690-6. PubMed ID: 21894500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
    Hata T; Fukunaga M; Murata K; Uemura Y; Fukuzaki T; Ota H; Ohue M; Ohnishi T; Tanaka N; Takemasa I; Mizushima T; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1657-63. PubMed ID: 23543294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
    Mizushima T; Tamagawa H; Matsuda C; Murata K; Fukunaga M; Ota H; Hasegawa J; Tsujie M; Fukuzaki T; Hata T; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Oncology; 2015; 89(3):152-8. PubMed ID: 25967649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
    Kusaba H; Esaki T; Kishimoto J; Uchino K; Arita S; Kumagai H; Mitsugi K; Akashi K; Baba E
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):29-34. PubMed ID: 23228984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
    Komatsu Y; Ishioka C; Shimada K; Yamada Y; Gamoh M; Sato A; Yamaguchi T; Yuki S; Morita S; Takahashi S; Goto R; Kurihara M
    BMC Cancer; 2015 Sep; 15():626. PubMed ID: 26353772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
    Matsuda C; Honda M; Tanaka C; Kondo K; Takahashi T; Kosugi C; Tokunaga Y; Takemoto H; Kim HM; Sakamoto J; Oba K; Mishima H
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1035-1041. PubMed ID: 29644459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
    Komatsu Y; Yuki S; Sogabe S; Fukushima H; Iwanaga I; Kudo M; Tateyama M; Meguro T; Uebayashi M; Saga A; Sakata Y; Asaka M
    Oncology; 2011; 80(1-2):70-5. PubMed ID: 21659785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
    Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
    N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
    Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
    Yoshida M; Goto M; Kii T; Nishitani H; Kawabe S; Kuwakado S; Asaishi K; Miyamoto T; Higuchi K
    Digestion; 2013; 87(1):59-64. PubMed ID: 23343971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
    Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
    Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial).
    Yoshida M; Muro K; Tsuji A; Hamamoto Y; Yoshino T; Yoshida K; Shirao K; Miyata Y; Takahari D; Takahashi T; Ohtsu A
    Eur J Cancer; 2015 May; 51(8):935-41. PubMed ID: 25837882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.